HonorHealth Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, HonorHealth Research Institute sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
HonorHealth Research Institute: 20 sponsored US clinical trials, 1 recruiting.
HonorHealth Research Institute sponsors 20 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Untreated Resectable Pancreatic Adenocarcinoma, with 1 trials.
Top-decile sponsor footprint
HonorHealth Research Institute ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
NCT07463599
The Seven Trial: Exploiting the Unfolded Protein Response
NCT06076837
Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine
NCT05175521
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
NCT05068752
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
NCT04669197
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
NCT03915444
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
NCT03138720
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
NCT05229588
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
NCT05004025
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
NCT04339426
Hair Loss Prevention Study for Pancreatic Cancer
NCT04492800
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
NCT03714555
Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients
NCT04291066
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
NCT03606642
Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns
NCT03599258
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
NCT03415854
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
NCT03410030
A Standardized Bundle Protocol to Optimize Outcomes With Patients Undergoing Gynecological Surgery
NCT03610425
Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy
NCT05374876
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 11 |
Therapeutic Areas
What is open in the HonorHealth Research Institute pipeline
1 recruiting of 20 indexed (5% open); 10 completed (50%).
Phase mix: 0 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Untreated Resectable Pancreatic Adenocarcinoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
HonorHealth Research Institute: open-pipeline peers nationwide
Peers matched on 20 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
HonorHealth Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Avera McKennan Hospital & University Health Center · 5% recruiting · 20 trials
- Integra LifeSciences Corporation · 5% recruiting · 60 trials
- Lumenis Be · 5% recruiting · 20 trials
- Nathan Kline Institute for Psychiatric Research · 5% recruiting · 20 trials
Related
What to do with this HonorHealth Research Institute page
20 registered trials is a research-attention snapshot, not an endorsement of HonorHealth Research Institute or any single study.
- 1 of HonorHealth Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Untreated Resectable Pancreatic Adenocarcinoma is the condition HonorHealth Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Untreated Resectable Pancreatic Adenocarcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
HonorHealth Research Institute pipeline card: 20 registered trials from official public datasets.Report a data error.